Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05751629 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
A Phase 2 study, sponsored by Tesaro.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT05751629 is a Phase 2 study that has completed, run by Tesaro. The registered enrollment target is 41 participants.
The verdict
NCT05751629, a Phase 2 study, has completed, sponsored by Tesaro.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The primary objective of this sub study is to evaluate the efficacy of the combination of TSR-042, bevacizumab, and niraparib in participants with advanced, relapsed, high-grade ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 2 prior lines of anticancer therapy, are PARP inhibitor naïve, and have platinum-resistant but not refractory disease. This study is a sub study of the master protocol - OPAL (NCT03574779).
Interventions
- DRUG Bevacizumab
- DRUG Niraparib
- DRUG Dostarlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-11-15 |
| Est. Completion | 2022-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05751629
The ClinicalTrials.gov registry entry for NCT05751629 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tesaro, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT05751629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05751629 about?
NCT05751629 is a clinical study titled "Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer". The primary objective of this sub study is to evaluate the efficacy of the combination of TSR-042, bevacizumab, and niraparib in participants with advanced, relapsed, high-grade ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 2 prior lines of anticancer therapy, are PARP...
What is the current status of trial NCT05751629?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2018-11-15. Estimated completion is 2022-04-01.
What interventions are being tested in trial NCT05751629?
The interventions under investigation include: Bevacizumab (DRUG), Niraparib (DRUG), Dostarlimab (DRUG).
Who is sponsoring clinical trial NCT05751629?
This trial is sponsored by Tesaro, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.